drugset / Trial / NCT02019758

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

NCT02019758

RandomizedParallel-groupDouble-blindTreatment

Summary

Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response. Participants: A total of up to 200 16-80 year old patients with a new diagnosis of eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a target of 122 randomized. Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will generate data for all three Aims

Timeline

Start
2015-01-01
Primary completion
2018-05
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 1 mg Oral
Comparator Fluticasone Other / unclassified 880 ug Oral